EyePoint Pharmaceuticals Statistics
Share Statistics
EyePoint Pharmaceuticals has 68.25M shares outstanding. The number of shares has increased by 9.58% in one year.
| Shares Outstanding | 68.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.75% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 61.98M |
| Failed to Deliver (FTD) Shares | 4.15K |
| FTD / Avg. Volume | 0.48% |
Short Selling Information
The latest short interest is 9.68M, so 14.18% of the outstanding shares have been sold short.
| Short Interest | 9.68M |
| Short % of Shares Out | 14.18% |
| Short % of Float | 16.07% |
| Short Ratio (days to cover) | 10.4 |
Valuation Ratios
The PE ratio is -12.38 and the forward PE ratio is -3.93.
| PE Ratio | -12.38 |
| Forward PE | -3.93 |
| PS Ratio | 19.04 |
| Forward PS | 35.6 |
| PB Ratio | 3.29 |
| P/FCF Ratio | -544.85 |
| PEG Ratio | n/a |
Enterprise Valuation
EyePoint Pharmaceuticals Inc. has an Enterprise Value (EV) of 600.32M.
| EV / Earnings | -8.48 |
| EV / Sales | 13.05 |
| EV / EBITDA | -8.7 |
| EV / EBIT | -8 |
| EV / FCF | -373.34 |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 0.
| Current Ratio | 5.45 |
| Quick Ratio | 5.39 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -60.2 |
Financial Efficiency
Return on equity (ROE) is -0.27% and return on capital (ROIC) is -27.71%.
| Return on Equity (ROE) | -0.27% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -27.71% |
| Revenue Per Employee | 380.31K |
| Profits Per Employee | -585.08K |
| Employee Count | 121 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 1.19 |
Taxes
| Income Tax | 83.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -61.79% in the last 52 weeks. The beta is 1.52, so EyePoint Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | -61.79% |
| 50-Day Moving Average | 9.82 |
| 200-Day Moving Average | 12.19 |
| Relative Strength Index (RSI) | 37.08 |
| Average Volume (20 Days) | 867.60K |
Income Statement
In the last 12 months, EyePoint Pharmaceuticals had revenue of $46.02M and earned -$70.80M in profits. Earnings per share was $-1.82.
| Revenue | 46.02M |
| Gross Profit | 41.39M |
| Operating Income | -75.07M |
| Net Income | -70.80M |
| EBITDA | -69.00M |
| EBIT | -75.07M |
| Earnings Per Share (EPS) | -1.82 |
Balance Sheet
The company has $281.26M in cash and $4.91M in debt, giving a net cash position of $276.36M.
| Cash & Cash Equivalents | 281.26M |
| Total Debt | 4.91M |
| Net Cash | 276.36M |
| Retained Earnings | -742.15M |
| Total Assets | 300.92M |
| Working Capital | 219.75M |
Cash Flow
In the last 12 months, operating cash flow was $1.88M and capital expenditures -$3.48M, giving a free cash flow of -$1.61M.
| Operating Cash Flow | 1.88M |
| Capital Expenditures | -3.48M |
| Free Cash Flow | -1.61M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 89.93%, with operating and profit margins of -163.13% and -153.84%.
| Gross Margin | 89.93% |
| Operating Margin | -163.13% |
| Pretax Margin | -153.66% |
| Profit Margin | -153.84% |
| EBITDA Margin | -149.94% |
| EBIT Margin | -163.13% |
| FCF Margin | -3.49% |
Dividends & Yields
EYPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.36% |
| FCF Yield | -0.32% |
Analyst Forecast
The average price target for EYPT is $25.5, which is 241.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.5 |
| Price Target Difference | 241.4% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Dec 9, 2020. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 9, 2020 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -0.04 |
| Piotroski F-Score | 2 |